Danaher (NYSE:DHR) Stock Unloaded by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold $15,001–$50,000 of Danaher stock from the Hern Family Foundation account on August 31, according to a filing disclosed September 25. He also reported selling holdings in several other companies in mid-September.
• Danaher reported stronger-than-expected quarterly results, with EPS of $1.94 and revenue of $6.26 billion; revenue increased 5.5% year over year.
• Danaher shares opened at $227.51, near analysts’ consensus price target of $230.23. The company declared a quarterly dividend of $0.40 per share, representing a 0.7% annualized yield.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Danaher Corporation NYSE: DHR. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on August 31st. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

Danaher Stock Performance

NYSE DHR opened at $227.51 on Tuesday. The stock's fifty day moving average is $206.57 and its two-hundred day moving average is $192.90. The firm has a market capitalization of $159.94 billion, a P/E ratio of 40.41, a price-to-earnings-growth ratio of 2.80 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the company earned $0.77 EPS. The company's revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 28.42%.

Institutional Trading of Danaher

Hedge funds have recently modified their holdings of the stock. EP Wealth Advisors LLC acquired a new position in Danaher in the second quarter valued at $3,807,000. Puzo Michael J purchased a new stake in shares of Danaher in the 2nd quarter valued at about $8,624,000. Madison Asset Management LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at about $85,451,000. First Nebraska Trust Co acquired a new stake in shares of Danaher in the 2nd quarter valued at about $14,106,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Danaher during the second quarter worth approximately $11,800,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on DHR shares. Royal Bank Of Canada upped their price objective on Danaher from $200.00 to $215.00 and gave the company an "outperform" rating in a report on Wednesday, July 22nd. Wells Fargo & Company reduced their target price on Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 22nd. Guggenheim decreased their price target on Danaher from $235.00 to $200.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. TD Cowen lowered their price target on Danaher from $240.00 to $236.00 and set a "buy" rating for the company in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $230.23.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.